Rapamycin: something old, something new, sometimes borrowed and now renewed.

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• The molecular target of rapamycin (mTOR) pathway regulates critical cellular processes like growth, proliferation, angiogenesis, autophagy, and metabolism.
• Sirolimus (rapamycin), the first mTOR inhibitor, was discovered over 30 years ago.
• Recent development of numerous rapalogs indicates a resurgence of interest in mTOR pathway modulation.

Purpose of the Study:

• To review the significance of the mTOR pathway.
• To discuss the development and characteristics of newer rapalogs.
• To highlight the potential therapeutic applications and economic impact of mTOR inhibitors.

Main Methods:

• Literature review of mTOR pathway research.
• Analysis of pharmacokinetic and pharmacodynamic data for sirolimus and rapalogs.
• Evaluation of potential clinical applications and market trends for mTOR inhibitors.

Main Results:

• The mTOR pathway is integral to fundamental cellular functions.
• Newer rapalogs share structural similarities with sirolimus, with minor pharmacokinetic differences but comparable pharmacodynamic effects and tolerability.
• Patent expiration of sirolimus is anticipated to reduce costs.

Conclusions:

• The mTOR pathway remains a key target for therapeutic intervention.
• Rapalogs represent a promising class of drugs with diverse potential applications.
• Increased focus on sirolimus and its analogs is warranted due to their therapeutic potential and expected cost-effectiveness.